Market Place
Sourcing Support
Nuntius Partners With Taiho Pharma To Develop Next-Gen mRNA Therapies
15 Aug 2024 //
BUSINESSWIRE
Taiho Ventures Expands Investment Pool to $400 Million
08 Jan 2024 //
PR NEWSWIRE
Taiho Pharma`s Lytgobi (futibatinib) Receives Approval in Europe
19 Oct 2023 //
EMA
Taiho and Phost’in License Agreement on the 1st-in-Class GnT-V Inhi. PhOx430
29 Aug 2023 //
PRESS RELEASE
FDA Approves LONSURF in Combination With Bevacizumab for mCRC
02 Aug 2023 //
PR NEWSWIRE
Taiho`s Lytgobi (futibatinib) Receives Approval in Europe
18 Jul 2023 //
EMA
U.S. FDA Accepts for Priority Review Taiho Onc`s sNDA for Trifluridine/Tipiracil
18 Apr 2023 //
PR NEWSWIRE
Taiho Pharmaceutical Obtain Additional Indication for Oral Anticancer Agent TS-1
24 Nov 2022 //
PRESS RELEASE
Drug Combination Meets Survival Endpoint in Ph III Pivotal Trial With RMCC
12 Sep 2022 //
BUSINESSWIRE
Cullinan, Taiho Pharma Complete Agreement for Collaboration on CLN-081/TAS6417
23 Jun 2022 //
GLOBENEWSWIRE
Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug
13 May 2022 //
BIOPHARMADIVE
Taiho pays to claw back licensing rights to lung cancer med
12 May 2022 //
FIERCEBIOTECH
Taiho Pharma Obtains Approval to Manufacture and Market Arokaris I.V. Infusion
28 Mar 2022 //
GLOBENEWSWIRE
Remiges Ventures launches new life science incubator
09 Apr 2021 //
BIOSPECTRUMASIA
Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor
23 Mar 2021 //
PRESS RELEASE
Taiho TAS-116, an Oral HSP90 Inhibitor, Shows Significantly Prolonged
22 Feb 2021 //
TAIHO
Taiho signs drug licensing deal with Lung Therapeutics in Japan
12 Nov 2020 //
PHARMACEUTICAL-TECHNOLOGY
Taiho Submits Application for Additional Dosage Administration 5-HT3 Receptor
15 Jun 2020 //
PRESS RELEASE
Arcus Biosciences & Taiho Jointly Announce Taiho’s Exercise Zimberelimab
26 Feb 2020 //
BUSINESSWIRE
KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal
07 Jan 2020 //
FIERCE BIOTECH
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
06 Jan 2020 //
PRESS RELEASE
Taiho Pharmaceuticals moves US court against Natco on generic cancer drug
03 Jan 2020 //
ECONOMICTIMES
LONSURF®trifluridine/tipiracil Receives Marketing Authorization EU for Patient
05 Sep 2019 //
BUSINESSWIRE
Taiho Pharmaceutical Invests in New Venture Capital Fund
28 Aug 2019 //
PRNASIA
Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data
18 Jan 2019 //
BUSINESSWIRE
Taiho antes up $250M for its venture arm it gets serious ‘global oncology’ deals
17 Oct 2018 //
ENDPTS
Seeking global deals, Taiho swells its U.S.-based VC fund to $300M
16 Oct 2018 //
FIERCE BIOTECH
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF®
07 Jun 2018 //
PR NEWSWIRE
Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF®
06 Mar 2018 //
NEWSWIRE
Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma
20 Sep 2017 //
BIOSPACE
OSE, Servier ink $10.7M deal to develop autoimmune drug
28 Dec 2016 //
FIERCE BIOTECH
Longitude plots a course to a $525M biotech fund, new Taiho group targets cancer
11 May 2016 //
FIERCE BIOTECH
Taiho Pharma Forms Venture Arm in California to Foster Cancer Biotech Start-ups
10 May 2016 //
BIOSPACE
CHMP Issues Opinion for LONSURF for Refractory Metastatic Colorectal Cancer
29 Feb 2016 //
PR NEWSWIRE
Soft tissue sarcoma drug approved in Japan
29 Sep 2015 //
BIOSPECTRUM ASIA
Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug
15 Jun 2015 //
NEWS MEDICAL
Taiho Submits Colorectal Cancer Drug In Europe
03 Mar 2015 //
PHARMATIMES
Speedy US Review for J&J Sarcoma Drug Yondelis
03 Feb 2015 //
PHARMA TIMES
